首页> 外文期刊>Neuropharmacology >Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.
【24h】

Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.

机译:在人NMDA(GluN1 / GluN2A)受体上,非竞争性N-甲基-D-天冬氨酸(NMDA)通道阻断剂美金刚的效力,电压依赖性,激动剂浓度依赖性,阻断动力学和部分释放。

获取原文
获取原文并翻译 | 示例
           

摘要

Both the clinical tolerability and the symptomatic effects of memantine in the treatment of Alzheimer's disease have been attributed to its moderate affinity (IC(50) around 1 microM at -70 mV) for NMDA receptor channels and associated fast, double exponential blocking/unblocking kinetics and strong voltage-dependency. Most of these biophysical data have been obtained from rodent receptors. Some substances show large species-specific differences, so using human rather than rodent receptors and tissue may highlight important differences in the effects of drugs. In the present study we compared the potency of memantine, ketamine and (+)MK-801 in binding to NMDA receptors in post-mortem human cortical tissue and to antagonize intracellular Ca(2+) responses of human GluN1/GluN2A receptors expressed in HEK-293 cells. In addition, the biophysical properties of memantine and ketamine were compared using patch clamp recordings from these cells. Memantine was confirmed to be a moderate affinity (IC(50) at -70 mV of 0.79+/-0.02 microM, Hill=0.92+/-0.02), strongly voltage-dependent (delta=0.90+/-0.09) uncompetitive antagonist of human GluN1/GluN2A receptors. Moreover, the rapid double exponential blocking kinetics (e.g. at 10 microM - onset tau(fast)=273+/-25 ms (weight 69%), onset tau(slow)=2756+/-296 ms, offset tau(fast)=415+/-82 ms (weight 38%) offset tau(slow)=5107+/-1204 ms) and partial untrapping (around 20%) previously reported for memantine on rodent receptors were confirmed for human receptors. Ketamine showed similar potency (IC(50) at -70 mV of 0.71+/-0.03 microM, Hill=0.84+/-0.02) but somewhat less pronounced voltage-dependency (delta=0.79+/-0.04), slower, single exponential kinetics (ketamine: k(on)=0.15+/-0.05 x 10(6)M(-1)s(-1), k(off)=0.22+/-0.05 s(-1)c.f. memantine following normalization k(on)=0.32+/-0.11 x 10(6)M(-1)s(-1), k(off)=0.53+/-0.10s(-1)) and was fully trapped. The present data closely match previously reported data from studies in rodent receptors and suggest that the proposed mechanism of action of memantine in Alzheimer's disease as a fast, voltage-dependent open-channel blocker of NMDA receptors can be confirmed for human NMDA receptors.
机译:美金刚在阿尔茨海默氏病治疗中的临床耐受性和症状作用均归因于其对NMDA受体通道的中等亲和力(IC(50)在-70 mV时约1 microM)和相关的快速,双指数阻断/解锁动力学和强电压依赖性。这些生物物理数据大多数是从啮齿动物受体获得的。有些物质显示出物种特异性差异很大,因此使用人类而不是啮齿动物受体和组织可能会突出显示药物作用的重要差异。在本研究中,我们比较了美金刚,氯胺酮和(+)MK-801与死后人类皮层组织中NMDA受体结合以及拮抗HEK中表达的人类GluN1 / GluN2A受体细胞内Ca(2+)反应的能力。 -293细胞。另外,使用来自这些细胞的膜片钳记录比较了美金刚和氯胺酮的生物物理特性。美金刚胺被确认为中等亲和力(IC(50)在-70 mV为0.79 +/- 0.02 microM,Hill = 0.92 +/- 0.02),强竞争性电压依赖性(δ= 0.90 +/- 0.09)的非竞争性拮抗剂人类GluN1 / GluN2A受体。此外,快速的双指数阻断动力学(例如,在10 microM下-起始tau(快速)= 273 +/- 25 ms(重量69%),起始tau(慢)= 2756 +/- 296 ms,偏移tau(快速)在人类啮齿类动物受体上证实了美金刚胺先前报道的= 415 +/- 82 ms(重量38%)偏移tau(慢)= 5107 +/- 1204 ms)和部分释放(约20%)。氯胺酮显示出相似的效价(IC(50)在-70 mV时为0.71 +/- 0.03 microM,Hill = 0.84 +/- 0.02),但电压依赖性(δ= 0.79 +/- 0.04)不太明显,较慢,单指数动力学(氯胺酮:k(on)= 0.15 +/- 0.05 x 10(6)M(-1)s(-1),k(off)= 0.22 +/- 0.05 s(-1)cf美金刚在归一化k之后(on)= 0.32 +/- 0.11 x 10(6)M(-1)s(-1),k(off)= 0.53 +/- 0.10s(-1))并被完全捕获。目前的数据与先前在啮齿类动物受体研究中报道的数据非常吻合,表明美金刚在阿尔茨海默氏病中作为一种快速,电压依赖性的NMDA受体开放通道阻滞剂的作用机制可以被人类NMDA受体证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号